# The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma

> **NCT02249312** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 38 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** BIIL 284 BS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02249312
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2000-04
- **Final completion:** —
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249312, "The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT02249312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*